The anticarcinogenic effect of trans-11 18:1 is dependent on its conversion to cis-9, trans-11 CLA by delta9-desaturase in rats.
The present study was designed to determine whether the ability of vaccenic acid (trans-11 18:1; VA) to reduce the risk of chemically induced mammary carcinogenesis in rats is direct or is mediated via conversion to cis-9, trans-11 conjugated linoleic acid (CLA). We previously reported that dietary VA caused a dose-dependent increase in the accumulation of CLA in the mammary fat pad, which was accompanied by a parallel decrease in the risk of mammary tumorigenesis. Specifically, our objective was to determine whether inhibiting Delta9-desaturase with cyclopropenoic fatty acids, supplied by sterculic oil (SO), would reverse the cancer-protective effect observed with a dietary supplement of VA-enriched butter. Female Sprague-Dawley rats were injected with a single dose of carcinogen (methylnitrosourea) and were fed 1 of 4 diets: 1) low VA (0.13% of diet), 2) low VA + SO (0.4% of diet), 3) high VA (1.60% of diet), and 4) high VA + SO. After 6 wk, the mammary glands were evaluated histologically for the appearance of premalignant lesions and were stained with bromodeoxyuridine to determine the extent of cell proliferation, and fatty acids were analyzed in plasma, liver, and mammary fat pad. The VA-enriched diet increased the tissue content of CLA, reduced the risk of developing premalignant lesions, and decreased the proliferative activity of premalignant cells in the mammary gland. Treatment with SO reversed the effects of VA. The anticarcinogenic effect of VA is predominantly, perhaps exclusively, mediated through its conversion to cis-9, trans-11 CLA via Delta9-desaturase, and when this conversion is blocked by SO, the biological response to VA is attenuated.
Department of Animal Science, Cornell University, Ithaca, NY 14853, USA.
Adam L
AL
Lock
Benjamin A
BA
Corl
David M
DM
Barbano
Dale E
DE
Bauman
Clement
C
Ip
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D004032:Diet; D005227:Fatty Acids / Q000097:blood*; D005260:Female; D044243:Linoleic Acids, Conjugated / Q000096:biosynthesis*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D015674:Mammary Neoplasms, Animal / Q000517:prevention & control*; D009829:Oleic Acids / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013230:Stearoyl-CoA Desaturase / Q000187:drug effects*
D005227:Fatty Acids; D044243:Linoleic Acids, Conjugated; D009829:Oleic Acids; D013230:Stearoyl-CoA Desaturase; C050413:11-octadecenoic acid